Paper
1
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
Authors
Florencia Rowdo,Gu Xiao
Galina Khramtsova,John Nguyen,Olufunmilayo Olopade,Rachel Martini,Brian Stonaker,Richard Boateng,Joseph Oppong,Ernest Adjei,Baffour Awuah,Ishmael Kyei,Francis Aitpillah,Michael Adinku,Kwasi Ankomah,Ernest Osei‐Bonsu,Kofi Gyan,Nasser Altorki,Esther Cheng,Paula Ginter,Syed Hoda,Lisa Newman,Olivier Elemento,Melissa Davis,Maria Martín,Jill Bargonetti
+24 authors
,María MartinPublished
Jun 22, 2023
Show more
Save
Tip1
TipSave